CPT® Code 0539T

Deleted

1. Indications

The indications for the administration of Chimeric antigen receptor T-cell (CAR-T) therapy include the following:

• Relapsed or Refractory B-cell Malignancies This therapy is indicated for patients with certain types of B-cell cancers, including acute lymphoblastic leukemia (ALL) and large B-cell lymphoma, who have not responded to standard treatments or have experienced a relapse after initial therapy.
• Specific Cancer Types CAR-T therapy is particularly indicated for patients diagnosed with specific hematologic malignancies that express target antigens recognized by the engineered T-cells, allowing for targeted treatment of the cancer.

2. Procedure

The procedure for Chimeric antigen receptor T-cell (CAR-T) therapy involves several critical steps, each essential for the successful preparation and administration of the therapy:

• Step 1: Blood Collection The process begins with the collection of blood from the patient, which may occur over one or more days. This blood is necessary to isolate the T-lymphocytes that will be genetically modified.
• Step 2: T-Cell Separation Once the blood is collected, the T-lymphocytes are separated from the other components of the blood using a process called leukapheresis. This step ensures that a sufficient quantity of T-cells is available for the subsequent genetic modification.
• Step 3: Genetic Engineering The isolated T-lymphocytes are then taken to a laboratory or manufacturing facility, where they undergo genetic engineering. An inactive virus is introduced into the T-cells, which carries the genetic instructions to produce chimeric antigen receptors (CARs) on the surface of the T-cells.
• Step 4: Expansion of CAR-T Cells After the T-cells are modified to express CARs, they are cultured and expanded in the laboratory until they number in the hundreds of millions. This expansion is crucial to ensure that there are enough CAR-T cells to effectively target and destroy cancer cells upon administration.
• Step 5: Lymphodepleting Chemotherapy While the CAR-T cells are being manufactured, the patient receives lymphocytic cell-depleting chemotherapy. This treatment is designed to reduce the number of existing lymphocytes in the patient's body, creating a more favorable environment for the infused CAR-T cells to thrive and function effectively.
• Step 6: Infusion of CAR-T Cells Once the CAR-T cells are ready and the patient has completed the preparatory chemotherapy, the modified T-cells are infused back into the patient. This step marks the beginning of the therapeutic action, as the CAR-T cells will now seek out and attack cancer cells in the body.

3. Post-Procedure

After the administration of Chimeric antigen receptor T-cell (CAR-T) therapy, patients are monitored closely for any potential side effects and to assess the effectiveness of the treatment. Common post-procedure care includes managing symptoms related to cytokine release syndrome (CRS), which can occur as the CAR-T cells activate and proliferate. Patients may also require supportive care to address any complications arising from the therapy. The persistence of CAR-T cells in the patient's body is expected to provide ongoing surveillance against cancer recurrence, and follow-up appointments are essential to evaluate the long-term outcomes of the therapy.